Akanda has multiple gateways to international markets for EU GMP medical cannabis

$3.8B
Size of European Cannabis Market by 20251
Cellen Logo Canmart Logo Touragen Logo Holigen Logo
  1. Market estimates for Europe per Prohibition Partners: https://prohibitionpartners.com

UK BASED DISTRIBUTION

Akanda's wholly owned subsidiary CanMart Ltd. is one of a limited number of fully licensed UK importers and wholesalers of medical cannabis to patients in the UK. CanMart provides route to market for cannabis grown at Bophelo's campus in Lesotho as well as an independent "open marketplace" supply chain solution into the UK for registered global cannabis companies looking to enter the European market.

LEARN MORE ABOUT CANMART

Akanda owns a one-of-a-kind cannabis operation in Portugal - Holigen. Holigen consists of a high-quality 20,000 square foot indoor facility located near Lisbon (in Sintra) dedicated to the cultivation of high-THC premium cannabis, one of a limited number of fully certified EU GMP of its kind in Europe, as well as a large seven million square foot (180+ acres) outdoor facility located two hours south in Aljustrel. Combined, these facilities provide the flexibility of capacity in Portugal to produce two tonnes of 1P premium indoor cannabis, over 100 tonnes of 1P outdoor cannabis, and over eight tonnes of 3P manufacturing capacity annually.

LEARN MORE ABOUT HOLIGEN

UK Patient Access

Akanda is partnered with UK digital healthcare leader Cellen and its fully integrated pain service to provide access to cannabis based medication for patients in need. Cellen's Leva Clinic (CQC registered) is the first fully online clinic for patients with chronic pain partnered with the NHS and Boots. Leva's multi disciplinary clinical team comprises of expert clinicians, clinical psychologists, physiotherapists and nurse consultants. The team supports patients through personalised online care plans.

LEARN MORE ABOUT CELLEN

EUROPEAN DISTRIBUTION

Through a processing and distribution agreement with Cantourage GmbH, Bophelo has secured a path to the rapidly growing European medical cannabis market for products cultivated in the Kingdom of Lesotho in Southern Africa. Bophelo plans to export cannabis starting material to Cantourage for processing into certified medical cannabis products with the first EU sales targeted for 2022.

LEARN MORE ABOUT CANTOURAGE